Browse

AI Prognosis: The release of Claude Science suggests big model makers are getting serious about real science, and not just flashy problems.

BridgeBio Pharma has reloaded with about $1 billion in a preferred equity deal to bolster its reserves ahead of three potential drug launches over the next year. The California biotech, which for…

Researchers have created what they say may count as the first synthetic cell, and have started a public benefit corporation to share the technology with other scientists.  It’s a piece…